Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Other Non-Current Assets (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Other Non-Current Assets for 14 consecutive years, with $5.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets fell 16.58% year-over-year to $5.4 million, compared with a TTM value of $5.4 million through Dec 2025, down 16.58%, and an annual FY2025 reading of $5.4 million, down 16.58% over the prior year.
  • Other Non-Current Assets was $5.4 million for Q4 2025 at Heron Therapeutics, down from $5.9 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $18.0 million in Q1 2022 and bottomed at $346000.0 in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $8.9 million, with a median of $7.4 million recorded in 2024.
  • The sharpest move saw Other Non-Current Assets skyrocketed 5095.66% in 2022, then plummeted 51.71% in 2023.
  • Year by year, Other Non-Current Assets stood at $17.7 million in 2021, then decreased by 11.34% to $15.7 million in 2022, then tumbled by 48.27% to $8.1 million in 2023, then fell by 20.24% to $6.5 million in 2024, then decreased by 16.58% to $5.4 million in 2025.
  • Business Quant data shows Other Non-Current Assets for HRTX at $5.4 million in Q4 2025, $5.9 million in Q3 2025, and $6.1 million in Q2 2025.